Stockscreener 앱 받기
16.39
0.31%
0.05
전일 마감가:
$16.34
열려 있는:
$16.39
하루 거래량:
724.29K
Relative Volume:
0.89
시가총액:
$2.10B
수익:
-
순이익/손실:
-
주가수익비율:
-7.6042
EPS:
-2.1554
순현금흐름:
-
1주 성능:
+6.91%
1개월 성능:
+14.78%
6개월 성능:
+41.54%
1년 성능:
+0.00%
1일 변동 폭
$15.98
$16.62
1주일 범위
$14.77
$16.78
52주 변동 폭
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
명칭
Generate Biomedicines Inc
전화
888-469-0055
주소
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
16.39 | 2.05B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | H.C. Wainwright | Buy |
| 2026-03-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 개시 | Goldman | Buy |
| 2026-03-24 | 개시 | Guggenheim | Buy |
| 2026-03-24 | 개시 | Morgan Stanley | Overweight |
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
모두보기
Generate Biomedicines Inc 주식(GENB)의 최신 뉴스
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Generate Biomedicines (GENB) Stock Price, News & Analysis - marketbeat.com
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines (GENB) Slips 4.4% to $13.85 as Biotech Uncertainty Weighs on SharesModified Schiff - vinanet.vn
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Rallies 4.36% as Biotech Sentiment ShiftsMomentum Stock Picks - vinanet.vn
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Edges Lower as Stock Hovers Near Support LevelsBPI Reversal - vinanet.vn
What Just Happened with Generate Biomedicines' IPO - Kavout | AI
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Generate Biomedicines Inc. (GENB) Holds Steady Near Resistance Amid Low VolatilityHigh Dividend Factor - dars.gov.et
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Nvidia Invests in Biotech Company Generate Biomedicines - Intellectia AI
Significant Drop for Generate Biomedicines (GENB) as Shares Decl - GuruFocus
Generate Biomedicines Plunges As Rally Suddenly Unwinds - TipRanks
Generate Biomedicines Inc. Q1 2026 Earnings: Pre-revenue Biotech Reports Wider-than-Expected Loss, Stock Slightly DownCore Business Growth - dars.gov.et
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines Inc (GENB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):